Zürich-based venture capital firm Redalpine has completed the final close of Redalpine Capital VIII (RAC VIII) after securing $250 million in an oversubscribed fundraise. The new capital brings the firm’s overall assets under management to more than $1.4 billion.

Founded in 2006 by serial entrepreneur Peter Niederhauser and molecular biologist Dr Michael Sidler, the firm focuses on companies at the intersection of software and science. Half of the investment team holds scientific qualifications in disciplines such as genomics, physics, and machine learning, alongside experienced operators and entrepreneurs.

RAC VIII plans to lead Seed and Series A financing rounds for roughly 20 early-stage European businesses chosen from more than 5,000 annual applications. Initial portfolio investments include Paris-based Arlequin AI, which develops topological neural networks for threat detection, and Munich-based Calliora, an AI operating platform for hospital economics. Other investments comprise Zurich-based Enact Intelligence, which builds sensory systems for robotics, Berlin-based Telli, a creator of end-to-end AI conversational agents, and London-based Helical, a developer of biological foundation models for pharmaceutical workflows.

Redalpine operates a multi-stage investment approach to support portfolio companies from early financing through to potential initial public offerings. Eleven portfolio businesses have completed exits since 2023, while companies funded under the previous early-stage fund, RAC VII, have raised over $1.1 billion in secondary capital since 2024.

Redalpine is a European venture capital firm headquartered in Zürich, Switzerland. The firm invests in early-stage technology and deep-tech companies across Europe, targeting Seed and Series A rounds through its multi-stage investment platform.